Salmosan was returned to the United Kingdom (UK) market in August 2008 by the Fish Vet Group (FVG) to increase the long-term efficacy of treatments against sea lice in the salmon industry by adding another product for use in rotation. Strategically rotating the limited medicines available is generally recognised as the best way for the producers in the food chain to guard against development of resistance to parasite treatments.
The Marketing Authorisation (MA) of Salmosan is supported by an extensive dossier of scientific evidence for the efficacy, safety, fish pathology and environmental impact. The Salmosan datasheet provides the directions for the safe and most effective use of the product, while ensuring minimal impact on the environment.
The use of Salmosan in Norway is subject to an emergency license from the Norwegian Medicines Agency which is granted on the basis of its full British MA and on the condition that it is used as described in the product’s datasheet.
FVG‘s priority for Salmosan is its sustained efficacy through correct use, for the long term benefit of the fish, the environment and the industry. FVG is investing in future treatments against sea lice, but recognises the immediate need to maintain the on-going efficacy of the treatments currently available.
Note to editors
Working with fish farmers, regulatory authorities, food processors, aquarists and aquaculture industry suppliers since 1995, Fish Vet Group provides a comprehensive range of clinical, technical and advisory services.
FVG promotes a sustainable aquaculture industry and supports a controlled, responsible and ethical use of products, within a legal framework, based on the most up-to-date scientific evidence.
For further information regarding correct use of Salmosan, data sheet and any other inquiries, please contact: